Why a Perfect Shipment Still Does Not Enter Germany

In September 2025, German importers with valid licences, signed contracts and paid-for goods stopped receiving import permits. Nothing was wrong with the cannabis. Nothing was wrong with the paperwork. Germany had used up its annual import allocation of 122 tonnes, and the Federal Institute for Drugs and Medical Devices stopped issuing permits until the ceiling was raised to about 192.5 tonnes in October 2025.

That gap is the most important fact about the German market for anyone supplying it from outside the EU. It is also the one suppliers discover last — usually while explaining to their own production team why a finished, tested, packed batch is sitting in a warehouse in Chanthaburi.

Everything below is organised around one question: what stops a shipment that has nothing wrong with it?

The quota is a national ceiling, and neither party controls it

Germany is party to the UN Single Convention on Narcotic Drugs, which obliges signatory states to estimate their annual requirement for narcotic substances and keep imports inside that estimate. In Germany the duty falls to BfArM's Federal Opium Agency, which sets the ceiling and issues the permits that draw against it.

The consequence is structural rather than bureaucratic. Import capacity is a shared, finite pool. Every permit issued to every importer in the country draws on the same allocation, so one importer's ability to receive goods in November depends on what the entire German market imported between January and October.

The 2025 episode was not a young market correcting itself. It was the predictable result of demand growing faster than an estimate set the year before. A supplier planning multi-year volumes into Germany should treat fourth-quarter quota exhaustion as a recurring scenario, not an anomaly.

What this changes in practice. Delivery schedules tied to calendar dates describe a hope. Delivery schedules tied to permit issuance describe reality. The distinction sounds pedantic until a contractual delivery window expires while the buyer waits for a permit the state is not currently issuing.

The permit chain runs through Germany and sets the clock for both sides

A German importer needs two separate authorisations, and they are not interchangeable.

The general licence under §4(1) MedCanG is a company-level authorisation from BfArM. It says this company may handle medicinal cannabis at all. It exists independently of any shipment, and a buyer either holds it or does not.

The per-shipment import authorisation under §12 MedCanG is issued for one specific consignment; under §14 MedCanG the procedural rules of the Betäubungsmittel-Außenhandelsverordnung apply to it. This is the permit that draws against the national quota, and the one that stopped being issued in September 2025.

Now the part that matters to a producer: Thailand issues export permission against the buyer's import permit. The German document must exist before the Thai one can. No relationship, arrangement or urgency reverses that sequence.

So the German side sets the calendar for both parties. A Thai supplier cannot compress the timeline by working faster, cannot run the export process in parallel, and cannot commit to a delivery date that precedes a permit nobody has applied for yet. A supplier promising fixed dates at signature is promising something outside its control.

The question to ask a German buyer before discussing price: where are you against your quota this year, and what is your current lead time on a §12 authorisation? A buyer who answers precisely has imported before. A buyer who finds the question unusual has not.

The second thing that stops a perfect shipment: an implicit GMP boundary

Cannabis flower enters the European Union as an active pharmaceutical ingredient. Germany expects GACP compliance at cultivation and EU-GMP at manufacturing, and those two obligations sit with different parties.

The Thai producer's contribution is cultivation and post-harvest processing at a GACP-certified site, plus batch documentation complete enough for a European qualified person to release against. The EU-GMP release step happens inside the EU, performed by the importer's own QP or a contracted manufacturer. No cultivation site in Thailand, Colombia or Lesotho performs it, because it is not a cultivation activity.

The division is uncontroversial until it reaches a contract. An agreement treating delivery of non-GMP-compliant product as immediate breach describes something no GACP-only origin can satisfy. We have met this clause in draft agreements more than once, and it is rarely a trap — usually a template written for a different kind of supplier and never adjusted.

The workable form is an explicit written carve-out for the supply of unfinished product, with the GMP obligation attached to whoever performs the release. Where the carve-out exists, both sides know what they are buying. Where it does not, the disagreement surfaces during drafting if you are lucky and during the first delivery if you are not.

One related asymmetry, while the subject is open: the importer generally gives no guarantee that GACP material will upgrade to GMP status after importation, and takes no responsibility for a failed batch upgrade. That risk sits with the producer. It is defensible — the producer controls the material — but it should be priced, not discovered.

The third: irradiation assumed by one side and not the other

Several German distributors specifically source non-irradiated flower, and few origins supply it consistently. Others run channels where irradiation is mandatory.

We do not irradiate: irradiation measurably reduces terpene content — the part of the product a pharmacist's patients notice.

The failure mode is not irradiation but the assumption. If the buyer's channel requires treated material and the specification was agreed without it, someone must perform and pay for that step late. Worse, the treated batch is no longer identical to the batch that was tested: the certificate of analysis on file now describes material that no longer exists in that form. A specification problem disguised as a logistics problem, and cheapest to solve in the first conversation.

The fourth: documentation that disagrees with itself

Customs authorities do not evaluate quality. They evaluate consistency. A shipment stops when the entity on the invoice differs from the entity on the GACP certificate, when the batch number on the certificate of analysis differs from the one on the packing list, or when the product description on the export permission does not match the import authorisation.

None of these are quality failures. All of them hold goods. The defence is unglamorous: one set of identifiers across every document, and a documentation set assembled before the shipment rather than during it.

The documentation set for a German shipment:

• Thai DTAM GACP certificate for the cultivation site, with number and validity dates;
• European GACP declaration — Control Union or equivalent;
• batch certificate of analysis from an independent laboratory, method base stated;
• the importer's §12 import authorisation, against which Thailand issues export permission;
• Thai export permission for the specific shipment;
• packing list, invoice and transport documents, all naming the same entity and the same batch.

What German buyers ask, in the order they ask it

From our own correspondence the sequence is consistent:

1. GACP status of the cultivation site, with certificate scope and validity.
2. Batch certificates of analysis to Ph. Eur. methods.
3. Current GMP status for processing and release — and specifically where that step happens.
4. Irradiation status.
5. Product specifications, packaging format, minimum order quantity.
6. Which European markets have already been supplied, and by which route.

Questions three and six separate suppliers from one another. Anyone can send a certificate. Fewer can explain where the GMP boundary sits in their arrangement. Fewer still have a route that has already cleared customs.

What changed in 2024, and why the constraint moved

On 1 April 2024 the CanG package took effect, including the Medizinal-Cannabisgesetz. Medical cannabis left the Narcotics Act and became a prescription-only medicine under its own law. Prescribing became simpler and volumes rose sharply.

The significance for a supplier is not the headline. It is that demand stopped being the binding constraint. Before 2024 the question was whether German patients would get enough prescriptions. Since 2024 the question is whether the import machinery — permits, quotas, quality boundaries, documentation — can move the volume demand has already created. Every failure mode on this page is downstream of that shift.

Our position

EU-GACP: our Sabai Sabai Farm site in Chanthaburi holds a Control Union GAP & GACP declaration to the WHO and EMA guidelines (valid to September 2027) and Thai DTAM Cannabis GACP certification (TH-GACP 87/2568, 4,104 m², valid to September 2028).

Flower from our sites has been imported into Germany by our clients, alongside Portugal and Switzerland. We run the upstream chain in-house: phenohunting from seed, cultivation, harvest, drying, curing and packaging. The EU-GMP step sits with the importer or its contracted manufacturer, as described above.

Fifteen flowering rooms, installed capacity around 900 kg per month, cultivar drops roughly every 10 days. Flower is hand-trimmed and not irradiated.

Before you contract with any Thai supplier

• A GACP certificate with number and validity dates, not a photograph of a wall plaque.
• A recent batch COA with methods stated, ideally Ph. Eur.
• A written statement on irradiation, before the specification is agreed.
• A clear answer to where GMP release occurs and who holds that obligation.
• Evidence that the supplier's material has cleared customs somewhere in the EU before.

And one question for yourself rather than the supplier: where is your quota position this year, and does your delivery schedule depend on a permit you do not yet hold?

For supply discussions: export@elite-organic.com